(Q37770721)

22 August 2017

1 reference

title

Antiretroviral therapy and management of HIV infection (English)

1 reference

22 August 2017

0 references

anti-retroviral agent

0 references

2

Steven G Deeks

1 reference

22 August 2017

Paul A Volberding

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

376

1 reference

22 August 2017

issue

9734

1 reference

22 August 2017

page(s)

49-62

1 reference

Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Changes in the risk of death after HIV seroconversion compared with mortality in the general population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Survival of persons with and without HIV infection in Denmark, 1995-2005.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

AIDS in America--forgotten but not gone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Chimpanzee reservoirs of pandemic and nonpandemic HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Targeting early infection to prevent HIV-1 mucosal transmission.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Clinical and epidemiologic features of primary HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

High rates of forward transmission events after acute/early HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

T cell dynamics in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

The dynamics of CD4+ T-cell depletion in HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Pathogenesis of HIV infection: what the virus spares is as important as what it destroys

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Interleukin-2 therapy in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Effect of early versus deferred antiretroviral therapy for HIV on survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

HIV RNA level in early infection is predicted by viral load in the transmission source

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

A whole-genome association study of major determinants for host control of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Response to antiretroviral therapy after a single, peripartum dose of nevirapine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Antiretroviral-drug resistance among patients recently infected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Transmission of drug-resistant HIV-1 is stabilizing in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

HLA-B*5701 screening for hypersensitivity to abacavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Time to hit HIV, early and hard.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

The cost effectiveness of combination antiretroviral therapy for HIV disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Myelomeningocele in a child with intrauterine exposure to efavirenz.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

CCR5 deficiency increases risk of symptomatic West Nile virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

CD4+ count-guided interruption of antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Uncontrolled Viral Replication as a Risk Factor for Non-AIDS Severe Clinical Events in HIV-Infected Patients on Long-Term Antiretroviral Therapy: APROCO/COPILOTE (ANRS CO8) Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

HIV viremia and changes in kidney function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Continuous antiretroviral therapy decreases bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Maraviroc for previously treated patients with R5 HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Response to combination antiretroviral therapy: variation by age.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

The role of HIV in serious diseases other than AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

HIV rebounds from latently infected cells, rather than from continuing low-level replication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

The art of managing human immunodeficiency virus infection: a balancing act.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Accelerated immune senescence and HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Cognitive neuropsychology of HIV-associated neurocognitive disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Universal voluntary testing and treatment for prevention of HIV transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Investing to meet the scientific challenges of HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960676-9

7 January 2021

10.1016/S0140-6736(10)60676-9

Identifiers

DOI

1 reference

22 August 2017

1 reference